TY - JOUR AU - Gan, H. K. AU - Grothey, A. AU - Pond, G. R. AU - Moore, M. J. AU - Siu, L. L. AU - Sargent, D. PY - 2010 DA - 2010// TI - Randomized phase II trials: inevitable or inadvisable? JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.26.3343 DO - 10.1200/JCO.2009.26.3343 ID - Gan2010 ER - TY - JOUR AU - Simon, R. PY - 1989 DA - 1989// TI - Optimal two-stage designs for phase II clinical trials JO - Control Clin Trials VL - 10 UR - https://doi.org/10.1016/0197-2456(89)90015-9 DO - 10.1016/0197-2456(89)90015-9 ID - Simon1989 ER - TY - JOUR AU - Sharma, M. R. AU - Stadler, W. M. AU - Ratain, M. J. PY - 2011 DA - 2011// TI - Randomized phase II trials: a long-term investment with promising returns JO - J Natl Cancer Inst VL - 103 UR - https://doi.org/10.1093/jnci/djr218 DO - 10.1093/jnci/djr218 ID - Sharma2011 ER - TY - JOUR AU - Shan, G. G. AU - Zhang, H. AU - Jiang, T. PY - 2016 DA - 2016// TI - Minimax and admissible adaptive two-stage designs in phase II clinical trials JO - BMC Med Res Methodol VL - 16 UR - https://doi.org/10.1186/s12874-016-0194-3 DO - 10.1186/s12874-016-0194-3 ID - Shan2016 ER - TY - JOUR AU - Shan, G. G. AU - Zhang, H. AU - Jiang, T. PY - 2017 DA - 2017// TI - Efficient confidence limits for adaptive one-arm two-stage clinical trials with binary endpoints JO - BMC Med Res Methodol VL - 17 UR - https://doi.org/10.1186/s12874-017-0297-5 DO - 10.1186/s12874-017-0297-5 ID - Shan2017 ER - TY - JOUR AU - Jung, S. -. H. AU - Sargent, D. J. PY - 2014 DA - 2014// TI - Randomized phase II clinical trials JO - J Biopharm Stat VL - 24 UR - https://doi.org/10.1080/10543406.2014.901343 DO - 10.1080/10543406.2014.901343 ID - Jung2014 ER - TY - JOUR AU - Khan, I. AU - Sarker, S. J. AU - Hackshaw, A. PY - 2012 DA - 2012// TI - Smaller sample sizes for phase II trials based on exact tests with actual error rates by trading-off their nominal levels of significance and power JO - Br J Cancer VL - 107 UR - https://doi.org/10.1038/bjc.2012.444 DO - 10.1038/bjc.2012.444 ID - Khan2012 ER - TY - JOUR AU - Fleming, T. R. PY - 1982 DA - 1982// TI - One-sample multiple testing procedure for phase II clinical trials JO - Biometrics. VL - 38 UR - https://doi.org/10.2307/2530297 DO - 10.2307/2530297 ID - Fleming1982 ER - TY - JOUR AU - Wason, J. M. AU - Jaki, T. PY - 2016 DA - 2016// TI - A review of statistical designs for improving the efficiency of phase II studies in oncology JO - Stat Methods Med Res VL - 25 UR - https://doi.org/10.1177/0962280215588247 DO - 10.1177/0962280215588247 ID - Wason2016 ER - TY - JOUR AU - Mander, A. P. AU - Thompson, S. G. PY - 2010 DA - 2010// TI - Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials JO - Contemp Clin Trials VL - 31 UR - https://doi.org/10.1016/j.cct.2010.07.008 DO - 10.1016/j.cct.2010.07.008 ID - Mander2010 ER - TY - JOUR AU - Shuster, J. PY - 2002 DA - 2002// TI - Optimal two-stage designs for single arm phase II cancer trials JO - J Biopharm Stat VL - 12 UR - https://doi.org/10.1081/BIP-120005739 DO - 10.1081/BIP-120005739 ID - Shuster2002 ER - TY - JOUR AU - Jung, S. H. AU - Lee, T. AU - Kim, K. AU - George, S. L. PY - 2004 DA - 2004// TI - Admissible two-stage designs for phase II cancer clinical trials JO - Stat Med VL - 23 UR - https://doi.org/10.1002/sim.1600 DO - 10.1002/sim.1600 ID - Jung2004 ER - TY - JOUR AU - Jung, S. H. AU - Carey, M. AU - Kim, K. M. PY - 2001 DA - 2001// TI - Graphical search for two-stage designs for phase II clinical trials JO - Control Clin Trials VL - 22 UR - https://doi.org/10.1016/S0197-2456(01)00142-8 DO - 10.1016/S0197-2456(01)00142-8 ID - Jung2001 ER - TY - JOUR AU - McPherson, K. AU - Colton, T. PY - 1976 DA - 1976// JO - J Am Stat Assoc VL - 71 UR - https://doi.org/10.1080/01621459.1976.10481481 DO - 10.1080/01621459.1976.10481481 ID - McPherson1976 ER - TY - JOUR AU - Lee, J. J. AU - Feng, L. PY - 2005 DA - 2005// TI - Randomized phase II designs in cancer clinical trials: current status and future directions JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.03.197 DO - 10.1200/JCO.2005.03.197 ID - Lee2005 ER - TY - JOUR AU - Vickers, A. J. AU - Ballen, V. AU - Scher, H. I. PY - 2007 DA - 2007// TI - Setting the bar in phase II trials: the use of historical data for determining “go/no go” decision for definitive phase III testing JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-0909 DO - 10.1158/1078-0432.CCR-06-0909 ID - Vickers2007 ER - TY - JOUR AU - Brown, S. R. AU - Gregory, W. M. AU - Twelves, C. J. AU - Buyse, M. AU - Collinson, F. AU - Parmar, M. PY - 2011 DA - 2011// TI - Designing phase II trials in cancer: a systematic review and guidance JO - Br J Cancer VL - 105 UR - https://doi.org/10.1038/bjc.2011.235 DO - 10.1038/bjc.2011.235 ID - Brown2011 ER - TY - JOUR AU - Schiller, J. H. AU - Larson, T. AU - Ou, S. H. AU - Limentani, S. AU - Sandler, A. AU - Vokes, E. PY - 2009 DA - 2009// TI - Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.20.8355 DO - 10.1200/JCO.2008.20.8355 ID - Schiller2009 ER - TY - JOUR AU - Chen, T. T. PY - 1997 DA - 1997// TI - Optimal three-stage designs for phase II cancer clinical trials JO - Stat Med VL - 16 UR - https://doi.org/3.0.CO;2-1 DO - 3.0.CO;2-1 ID - Chen1997 ER - TY - JOUR AU - Thatcher, A. R. PY - 1964 DA - 1964// TI - Relationships between Bayesian and confidence limits for predictions JO - J R Stat Soc B VL - 26 ID - Thatcher1964 ER - TY - JOUR AU - Mander, A. P. AU - Wason, J. M. AU - Sweeting, M. J. AU - Thompson, S. G. PY - 2012 DA - 2012// TI - Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis JO - Pharm Stat VL - 11 UR - https://doi.org/10.1002/pst.501 DO - 10.1002/pst.501 ID - Mander2012 ER - TY - JOUR AU - Kim, J. AU - Schell, M. J. PY - 2019 DA - 2019// TI - Modified Simon’s minimax and optimal two-stage designs for single-arm phase II cancer clinical trials JO - Oncotarget. VL - 10 UR - https://doi.org/10.18632/oncotarget.26981 DO - 10.18632/oncotarget.26981 ID - Kim2019 ER - TY - STD TI - DeGroot MH. Optimal statistical decisions. New York; 1970. ID - ref23 ER - TY - JOUR AU - Ensign, L. G. AU - Gehan, E. A. AU - Kamen, D. S. AU - Thall, P. F. PY - 1994 DA - 1994// TI - An optimal three-stage design for phase II clinical trials JO - Stat Med VL - 13 UR - https://doi.org/10.1002/sim.4780131704 DO - 10.1002/sim.4780131704 ID - Ensign1994 ER - TY - JOUR AU - Jennison, C. AU - Turnbull, B. W. PY - 1983 DA - 1983// TI - Confidence intervals for a binomail parameter parameter following a multistage test with application to MSL-STD 105D and medical trials JO - Technometrics. VL - 25 UR - https://doi.org/10.1080/00401706.1983.10487819 DO - 10.1080/00401706.1983.10487819 ID - Jennison1983 ER - TY - JOUR AU - Kunz, C. U. AU - Kieser, M. PY - 2011 DA - 2011// TI - Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints JO - Methods Inf Med VL - 50 UR - https://doi.org/10.3414/ME10-01-0037 DO - 10.3414/ME10-01-0037 ID - Kunz2011 ER -